Testicular cancer - new approaches in surgery and systemic treatment

Poster Session 82

**Location:** Room Paris, North Hall (Level 1)

**Chairs:**
- M. Jewett, Toronto (CA)
- D.L. Nicol, London (GB)
- N. Nicolai, Milan (IT)

**Aims and objectives of this session**
This session will update the audience with new indications and outcome results from surgical approaches together with new systemic treatment options for patients with advanced germ cell cancer. In addition, quality of care issues will be discussed based on large registries.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (•) are 3 minutes in length, followed by 3 minutes for discussion.

1084

**Non-guideline concordant treatment of testicular cancer**
**By:** Paffenholz P., Pfister D., Heidenreich A.

**Institutes:** University Hospital Cologne, Dept. of Urology, Cologne, Germany

1085

**Testicular cancer in patients with learning disabilities in England from 2001-2015: A national cohort study**
**By:** Afshar M.², Jackson-Spence F.¹, De Santis M.³, Tanner J.-R.¹, Evison F.⁵, James N.³, Selby P.⁶, Patel P.⁷

**Institutes:** University of Birmingham, Medical School, Birmingham, United Kingdom, ²St George’s University Hospitals NHS Foundation Trust, Dept. of Urological Oncology, London, United Kingdom, ³University of Warwick, Cancer Research Unit, Coventry, United Kingdom, ⁴University Hospitals Birmingham NHS Foundation Trust, Dept. of Oncology, Birmingham, United Kingdom, ⁵University Hospitals Birmingham NHS Foundation Trust, Dept. of Informatics, Birmingham, United Kingdom, ⁶University of Leeds, Leeds Institute of Cancer & Pathology, Leeds, United Kingdom, ⁷University of Birmingham, School of Cancer Sciences, Birmingham, United Kingdom

1086

**Reliability of frozen section examination in a large cohort of testicular masses: What did we learn?**
**By:** Vartolomei M.D.¹, Matei D.V.², Renne G.³, Tringali V.M.², Ferro M.², Bianchi R.², Russo A.², Cozzi G.², De Cobelli O.⁴

**Institutes:** University of Medicine and Pharmacy, Targu Mures, Romania and European Institute of Oncology, Dept. of Cell and Molecular Biology and Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Urology, Milan, Italy, ³European Institute of Oncology and University of Milan, Dept. of Urology, Milan, Italy

1087

**Diagnostic value of frozen section examination (FSE) during inguinal exploration in patients with inconclusive testicular lesions**
**By:** Fankhauser C.¹, Beyer J.², Roth L.¹, Sulser T.¹, Bode K.-P.², Moch H.³, Hermanns T.¹

**Institutes:** University Hospital Zurich, University of Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital Zurich, University of Zurich, Dept. of Oncology, Zurich, Switzerland, ³University Hospital Zurich, University of Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland

1088

**Safety of testicular prosthesis insertion at the time of radical orchiectomy for testis cancer in patients undergoing adjuvant therapies**
**By:** Musi G.¹, Cozzi G.¹, Bianchi R.¹, Mistretta F.A.¹, Tringali V.M.L.¹, Jereczeck B.A.², Nolé F.³, De
1089 Laparoscopic retroperitoneal lymph-node dissection (L-RPLND) is not only a staging procedure in stage I non-seminomatous germ-cell testicular tumors (NSGCTT): Mature data from a referral centre

By: Nicolai N.1, Tarabelloni N.2, Catanzaro M.1, Gasperoni F.2, Stagni S.1, Torelli T.1, Tesone A.1, Kungulli A.1, Necchi A.3, Giannatempo P.3, Raggi D.3, Colecchia M.4, Salvioni R.1, Piva L.1, Pizzocaro G.3, Biasoni D.1

Institutes: Fondazione Ircss Istituto Nazionale Tumori, Dept. of Urology, Milan, Italy, 2Mox-Dipartimento Di Matematica, Milano, Italy, 3Fondazione Ircss Istituto Nazionale Tumori, Dept. of Medical Oncology, Milan, Italy, 4Fondazione Ircss Istituto Nazionale Tumori, Dept. of Pathology, Milan, Italy, 5Fondazione Ircss Istituto Nazionale Tumori, Emeritus, Milan, Italy

1090 Primary retroperitoneal lymph node dissection (RPLND) in Stage II A/B seminoma patients without adjuvant treatment: A phase II trial (PRIMETEST)

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes: Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

1091 Surgical resection of residual tumours after adjuvant chemotherapy of germ cell (GC) tumour

By: Gonzalez F.1, Bossavy J-P.1, Otal P.2, Quintyn–Rant M.-L.3, Roumigué M.4, Chevreau C.5, Malavaud B.4

Institutes: 1Chu Toulouse Rangueil, Dept. of Vascular Surgery, Toulouse, France, 2Chu Toulouse Rangueil, Dept. of Radiology, Toulouse, France, 3Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, 4Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, 5Institut Universitaire Du Cancer, Dept. of Medical Oncology, Toulouse, France

1092 Complications and adjunctive surgical procedures in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) to define a tertial referral center

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes: Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

1093 Bone metastases in germ cell tumors: Surgical management and outcomes

By: Nini A.1, Konieczny M.2, Winter C.3, Lusch A.3, Krauspe R.2, Albers P.3

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Orthopedic Surgery, Düsseldorf, Germany, 3University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Urology, Düsseldorf, Germany

1094 Retinal toxicity after cisplatin-based chemotherapy in patients with testicular cancer

By: Gild P.1, Vetterlein M.1, Dieckmann K.P.2, Matthis C.3, Wagner W.3, Ludwig T.1, Meyer C.1, Soave A.1, Dulz S.4, Asselborn N.4, Oechsle K.5, Bokemeyer C.6, Becker A.1, Fisch M.1, Hartmann M.1, Chun F.1, Kluth L.A.1

Institutes: 1University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2Albertinen Hospital, Dept. of Urology, Hamburg, Germany, 3Bundeswehr Medical Center Hamburg, Dept. of Urology, Hamburg, Germany, 4University Medical Center Hamburg-Eppendorf, Dept. of Ophthalmology, Hamburg, Germany, 5University Medical Center Hamburg-Eppendorf, Dept. of Medical Oncology, Hamburg, Germany

1095 The features and management of late relapse of non-seminomatous germ cell tumours

By: Jay A., Aldiwni M., Wijayarathna S., Huddart R., Mayer E., Nicol D.

Institutes: Royal Marsden Hospital, Dept. of Urology, Chelsea, United Kingdom

1096 Incidence of secondary malignancies (SM) in patients (pts) with germ cell tumors (GCT) who received high-dose chemotherapy (HDCT): A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) database

Institutes:
Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase 2 Pazotest trial

By: Necchi A.¹, Lo Vullo S.², Giannatempo P.¹, Raggi D.¹, Calareso G.³, Togliardi E.⁴, Crippa F.⁵, Pennati M.⁶, Zaffaroni N.⁶, Perrone F.², Colecchia M.⁷, Nicolai N.⁸, Mariani L.², Salvioni R.⁸

Institutes: Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, Fondazione IRCCS Policlinico San Matteo, Dept. of Medical Oncology, Pavia, Italy, Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, Fondazione IRCCS Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Nuclear Medicine - PET Unit, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy

Final comments

N. Nicolai, Milan (IT)